108 related articles for article (PubMed ID: 7349145)
1. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
[No Abstract] [Full Text] [Related]
2. [The echocardiography in thalassemia major (author's transl)].
Musumeci S; Schiliro G; Romeo MA; Di Gregorio F; Russo G; Scibilia G
Pediatr Med Chir; 1981; 3(2-3):219-22. PubMed ID: 6211659
[TBL] [Abstract][Full Text] [Related]
3. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
[TBL] [Abstract][Full Text] [Related]
4. [Patient compliance in iron-chelating therapy of beta-thalassemia major].
Di Gregorio F; Romeo MA; Tasca R; Passaniti G
Minerva Pediatr; 1983 May; 35(10):489-93. PubMed ID: 6877194
[No Abstract] [Full Text] [Related]
5. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
6. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of beta-thalassemia.
Graziano J; Piomelli S
Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
[No Abstract] [Full Text] [Related]
8. Cardiac status in well-treated patients with thalassemia major.
Aessopos A; Farmakis D; Hatziliami A; Fragodimitri C; Karabatsos F; Joussef J; Mitilineou E; Diamanti-Kandaraki E; Meletis J; Karagiorga M
Eur J Haematol; 2004 Nov; 73(5):359-66. PubMed ID: 15458515
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of and obstacles to iron cardiomyopathy in thalassemia.
Peng CT; Chang JS; Wu KH; Tsai CH; Lin HS
Front Biosci; 2008 May; 13():5975-87. PubMed ID: 18508636
[TBL] [Abstract][Full Text] [Related]
10. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
[TBL] [Abstract][Full Text] [Related]
11. Spleen iron content is low in thalassemia.
Borgna-Pignatti C; De Stefano P; Bongo IG; Avato F; Cazzola M
Am J Pediatr Hematol Oncol; 1984; 6(3):340-3. PubMed ID: 6517228
[TBL] [Abstract][Full Text] [Related]
12. Bull's eye maculopathy with deferoxamine.
Bansal V; Elgarbly I; Ghanchi FD; Atkinson PL
Eur J Haematol; 2003 Jun; 70(6):420-1. PubMed ID: 12756028
[No Abstract] [Full Text] [Related]
13. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
Wali YA; Taqi A; Deghaidi A
Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
[TBL] [Abstract][Full Text] [Related]
14. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
Esposito L; Ferrara M; Ponte G
Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
[No Abstract] [Full Text] [Related]
15. Glucose tolerance and chelation therapy in patients with thalassaemia major.
Capra L; Atti G; De Sanctis V; Candini G
Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
[No Abstract] [Full Text] [Related]
16. Intensification of chelating-therapy in patients with thalassemia major.
Laws HJ; Göbel U; Christaras A; Janssen G
Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
[TBL] [Abstract][Full Text] [Related]
17. Congestive heart failure and treatment in thalassemia major.
Aessopos A; Kati M; Tsironi M
Hemoglobin; 2008; 32(1-2):63-73. PubMed ID: 18274984
[TBL] [Abstract][Full Text] [Related]
18. Intensive transfusion therapy in thalassemia major.
Beard ME; Necheles TF; Allen DM
Pediatrics; 1967 Nov; 40(5):911-5. PubMed ID: 6075668
[No Abstract] [Full Text] [Related]
19. Beta-thalassemia and pulmonary function.
Piatti G; Allegra L; Ambrosetti U; Cappellini MD; Turati F; Fiorelli G
Haematologica; 1999 Sep; 84(9):804-8. PubMed ID: 10477453
[TBL] [Abstract][Full Text] [Related]
20. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
Cavallaro L; Meo A; Busà G; Coglitore A; Sergi G; Satullo G; Donato A; Calabrò MP; Miceli M
Minerva Cardioangiol; 1993; 41(7-8):297-301. PubMed ID: 8233011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
